15.11.2016
- Sanofi and US biopharmaceutical company Mannkind have finally thrashed out an agreement to terminate their licensing deal for Afrezza inhalable insulin. The agreement will likely...
11.01.2016
- Sanofi has handed back rights to the inhaled insulin treatment Afrezza to US drug development company MannKind. Sales of Afrezza, which launched in the US in February last year...
13.08.2014
- Sanofi and MannKind Corporation have entered into a worldwide exclusive licensing agreement for development and commercialization of Afrezza (insulin human) Inhalation Powder, a...
